We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays.
- Authors
Sojeong Yun; Ji Hyeong Ryu; Joo Hee Jang; Hyunjoo Bae; Seung-Hyo Yoo; Ae-Ran Choi; Sung Jin Jo; Jihyang Lim; Jehoon Lee; Hyejin Ryu; Sung-Yeon Cho; Dong-Gun Lee; Jongmin Lee; Seok Chan Kim; Yeon-Joon Park; Hyeyoung Lee; Eun-Jee Oh
- Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody assays have high clinical utility in managing the pandemic. We compared antibody responses and seroconversion of coronavirus disease 2019 (COVID-19) patients using different immunoassays. Methods: We evaluated 12 commercial immunoassays, including three automated chemiluminescent immunoassays (Abbott, Roche, and Siemens), three enzyme immunoassays (Bio-Rad, Euroimmun, and Vircell), five lateral flow immunoassays (Boditech Med, SD biosensor, PCL, Sugentech, and Rapigen), and one surrogate neutralizing antibody assay (GenScript) in sequential samples from 49 COVID-19 patients and 10 seroconversion panels. Results: The positive percent agreement (PPA) of assays for a COVID-19 diagnosis ranged from 84.0% to 98.5% for all samples (>14 days after symptom onset), with IgM or IgA assays showing higher PPAs. Seroconversion responses varied across the assay type and disease severity. Assays targeting the spike or receptor-binding domain protein showed a tendency for early seroconversion detection and higher index values in patients with severe disease. Index values from SARS-CoV-2 binding antibody assays (three automated assays, one LFIA, and three EIAs) showed moderate to strong correlations with the neutralizing antibody percentage (r=0.517-0.874), and stronger correlations in patients with severe disease and in assays targeting spike protein. Agreement among the 12 assays was good (74.3%-96.4%) for detecting IgG or total antibodies. Conclusions: Positivity rates and seroconversion of SARS-CoV-2 antibodies vary depending on the assay kits, disease severity, and antigen target. This study contributes to a better understanding of antibody response in symptomatic COVID-19 patients using currently available assays.
- Subjects
SIEMENS AG; COVID-19; ANTIBODY formation; SARS-CoV-2; SEROCONVERSION; IMMUNOASSAY; IMMUNOGLOBULIN M
- Publication
Annals of Laboratory Medicine, 2021, Vol 41, Issue 6, p577
- ISSN
2234-3806
- Publication type
Article
- DOI
10.3343/alm.2021.41.6.577